CN105287382A - Preparation method of folic acid-chitosan modified curcumin nano-liposome - Google Patents
Preparation method of folic acid-chitosan modified curcumin nano-liposome Download PDFInfo
- Publication number
- CN105287382A CN105287382A CN201510671604.3A CN201510671604A CN105287382A CN 105287382 A CN105287382 A CN 105287382A CN 201510671604 A CN201510671604 A CN 201510671604A CN 105287382 A CN105287382 A CN 105287382A
- Authority
- CN
- China
- Prior art keywords
- folic acid
- chitosan
- solution
- curcumin
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a preparation method of a folic acid-chitosan modified curcumin nano-liposome. The folic acid-chitosan modified curcumin nano-liposome is prepared by embedding curcumin with a nano-liposome and modifying a folic acid-chitosan compound on the surface of the liposome. The mean grain size of the folic acid-chitosan modified curcumin nano-liposome prepared by the invention is 103.6+/-4.1nm, a zeta potential is 16.35+/-3.54mv, a coefficient of dispersion is 0.378+/-0.01 and a drug loading capacity reaches 35.7mg/g of phospholipid, and the nano-liposome shows a good storage stability at 25 DEG C. The nano-liposome also shows a good slow-release property, and the release rate of the nano-liposome, in a weakly acid environment, is rapider than that in a weakly alkaline environment. After 24h, only 17.4% the curcumin is released under pH7.4 and only 27.7% of the curcumin is released under pH5.5.
Description
Technical field
The present invention is specifically related to the preparation method of a kind of folic acid-chitosan-modified curcumin nano-lipid body, can be applied to the fields such as food, medicine, cosmetics further.
Background technology
Curcumin (curcumin, Cur) is the low-molecular-weight polyphenol compound extracted from Rhizoma Curcumae Longae rhizome, is applied to food and chemical industry as a kind of common coloring agent, spice and antiseptic.Curcumin has many physiologically actives because of it, as antioxidation, anti-inflammatory, antibacterial, the biological activity such as antiviral and anticancer, but, the poorly water-soluble of curcumin, poor heat stability, unstable under alkalescence and physiological environment, oral bioavailability rate is extremely low, limits its application in food and medicine industry.Along with the development of embedding techniques, microcapsule, micelle, complex nanometer granule, microemulsion and liposome (liposomes) etc. are used to embed curcumin, are intended to improve its bioavailability and expand its range of application.
Liposome main component is phospholipid and cholesterol, has good biocompatibility, can deliver hydrophilic, lipophilic and both sexes medicine, nutrient, functional component etc.Folic acid (folicacid, FA) i.e. pteroylglutamic acid, is present in most vegetables, is the vitamin B group of needed by human, and folacin receptor overexpression in kinds of tumor cells, folic acid is widely studied as cancerous cell targeted molecular.Under the catalytic action of N-hydroxy-succinamide and 1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride; chitosan (chitosan; CS) amino of molecule can produce folic acid-chitosan complexes with folic acid generation acylation reaction, is modified at surface of liposome by electrostatic interaction.
Film dispersion method is the most classical method of liposomal preparation, and this method is more suitable for embedding fat-soluble medicine.Dynamic high-pressure microfluidizer can produce the static pressure of 100 ~ 300MPa, makes the pulverizing of material generation Strong shear, high-speed impact, cavitation erosion, vibration and the effect such as expanded.Thin film dispersion can obtain the small particle diameter liposome of stable uniform in conjunction with dynamic high-pressure microjet method.
Summary of the invention
The object of the invention is to provide a kind of preparation method for optimizing folic acid-chitosan-modified curcumin nano-lipid body for prior art deficiency, to improve the stability of liposome, evaluate storage stability and the sustained release performance of folic acid-chitosan-modified curcumin nano-lipid body, for the exploitation of folic acid-chitosan-modified curcumin nano-lipid body provides theoretical foundation and Technical Reference.
The method of the invention comprises the following steps:
(1) synthesis of folic acid-chitosan complexes:
(1) used catalyst and each raw material and mol ratio thereof are: amino amount=6:9:9:10 in N-hydroxy-succinamide/1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride/folic acid/chitosan, N-hydroxy-succinamide, 1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride and folic acid is taken respectively by above-mentioned mol ratio, the folic acid of 0.150g/mL concentration is dissolved in dimethyl sulfoxide, activation 4h;
(2) be that the chitosan of 0.025g/mL adds in the glacial acetic acid solution of 0.3% by concentration, it is as clear as crystal that 200r/min continues stirring until solution;
(3): the folic acid solution that step (1) obtains slowly is joined in the chitosan solution that step (2) obtains, simultaneously with 200r/min Keep agitation reaction 16h;
(4) with 0.1M sodium hydroxide solution, step (3) gained product is adjusted to pH9.0, and is transferred in the bag filter of 3.5KDa, dialyse 2 days in the phosphate buffered solution and PBS of pH7.4, then dialyse 2 days in distilled water;
(5) by the lyophilization of step (4) gained solution, yellow spongy folic acid-chitosan complexes is obtained;
All operations all carries out under light protected environment;
(2) thin film dispersion-dynamic high-pressure microjet legal system is for curcumin nano-lipid body:
(1) each component of liposome raw material and percentage by weight thereof are: curcumin 0.05%-0.2%, soybean phospholipid 1.4%-5.6%, cholesterol 0.22%-0.88%, tween 80 0.4%-1.6%, phosphate buffered solution and the PBS of remaining to be pH6.5 concentration be 0.05M are 91.7%-97.9%; Take curcumin, soybean phospholipid, cholesterol and tween 80 respectively by above-mentioned percentage by weight, under 45 DEG C of water bath condition, be dissolved in 15mL dehydrated alcohol by 1g soybean phospholipid, each component is dissolved completely;
(2) reduce pressure step (1) gained solution on Rotary Evaporators removing dehydrated alcohol, forms homogeneous film;
(3) add the phosphate buffered solution (PBS) that pH6.5 concentration is 0.05M and wash film, form yellow thick Liposomal suspensions;
(4) with the Liposomal suspensions that high pressure Microfluidizer treatment step (3) obtains, pressure is 120MPa, and number of processes is 2 times, obtains yellow bright curcumin nano-lipid liquid solution;
(3) preparation of folic acid-chitosan-modified curcumin nano-lipid body:
(1) weight ratio of folic acid-chitosan complexes and phospholipid is 1:16.8; Be dissolved in the glacial acetic acid solution of 1% by folic acid-chitosan complexes that step () obtains by 5mg/mL, it is as clear as crystal that 200r/min continues stirring until solution;
(2) slowly join in step (two) gained curcumin nano-lipid liquid solution by above-mentioned quality by step (1) gained solution, 300r/min Keep agitation reaction 2h, obtains folic acid-chitosan-modified curcumin nano-lipid body.
The invention has the beneficial effects as follows: the folic acid-chitosan-modified curcumin nano-lipid body mean diameter of preparation is 103.6 ± 4.1nm, zeta current potential is 16.35 ± 3.54mv, the coefficient of dispersion is 0.378 ± 0.01, drug loading reaches 35.7mg/g phospholipid, good 25 DEG C of storage stabilities, under the environment of pH7.4 and pH5.5, slow-releasing is good, and controls the release of curcumin by changing pH.
Accompanying drawing explanation
Fig. 1 is the process route view of folic acid-chitosan-modified curcumin nano-lipid body;
Fig. 2 (a) is the grain size distribution of folic acid-chitosan-modified curcumin nano-lipid body;
Fig. 2 (b) is the microscopic appearance figure of folic acid-chitosan-modified curcumin nano-lipid body;
Fig. 3 is the sustained release performance of liposome;
In figure: NLs-Cur and FA-CS-NLs-Cur represents curcumin nano-lipid body and folic acid-chitosan-modified curcumin nano-lipid body respectively.
Detailed description of the invention
Raw material: soybean phospholipid (95%, Germany lipoidGmbH), cholesterol (Sigma.MKBF1936V), tween 80 (Shen, Shanghai space medicine), curcumin (98%, Aladdin reagent Shanghai company limited), chitosan (MW50000, deacylated tRNA degree 90%, Sigma-Aldrich), folic acid (Aladdin reagent Shanghai company limited), 1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride (Aladdin reagent Shanghai company limited), N-hydroxy-succinamide (Aladdin reagent Shanghai company limited).
Embodiment 1
(1) take 1.036gN-N-Hydroxysuccinimide, 1.725g1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride and 2.648g folic acid, be dissolved in 20mL dimethyl sulfoxide completely, place activation 4h.Taking 1.46g chitosan adds in the glacial acetic acid solution of 60mL0.3%, and 200r/min continues stirring until and dissolves completely.Chitosan solution is slowly added in the folic acid solution of activation, simultaneously with 200r/min Keep agitation reaction 16h.With 0.1M sodium hydroxide solution, gained product is adjusted to pH9.0, and is transferred in the bag filter of 3.5KDa, dialysis 2 days in the phosphate buffered solution (PBS) of pH7.4, then dialyse 2 days in distilled water, removing impurity.Gained sample lyophilization after dialysing, obtains yellow spongy folic acid-chitosan complexes.
(2) take 0.050g curcumin, 1.400g soybean phospholipid, 0.220g cholesterol, 0.400g tween 80 be dissolved in 28mL dehydrated alcohol completely, under 45 DEG C of water bath condition, vacuum rotating removing ethanol, forms homogeneous film.Add the phosphate buffered solution (PBS) that 100mLpH6.5 concentration is 0.05M and wash film, the even suspension of formation is thick liposome.Join in DHPM by thick liposome, under 120MPa condition, Micro Fluid process 2 times, namely prepares curcumin nano-lipid body.
(3) taking 0.050g step (1) gained folic acid-chitosan complexes is dissolved in the glacial acetic acid solution of 10mL1%, and it is as clear as crystal that 200r/min continues stirring until solution, obtains folic acid-chitosan complexes solution.Getting 60mL step (2) gained curcumin nano-lipid body slowly drops in 10mL folic acid-chitosan complexes solution, and 300r/min Keep agitation reaction 2h, obtains folic acid-chitosan-modified curcumin nano-lipid body.Obtained folic acid-chitosan-modified curcumin nano-lipid body is clear yellow solution, and drug loading is 35.5mg/g phospholipid, and mean diameter is 104.9nm, zeta current potential is 16.08mv, and the coefficient of dispersion is 0.378; Folic acid-chitosan-modified curcumin nano-lipid body 24h curcumin burst size under pH7.4 environment is 17.3%, and under pH5.5 environment, 24h curcumin burst size is 27.5%; 25 DEG C store one month, and the particle diameter of folic acid-chitosan-modified curcumin nano-lipid body, surface point position and curcumin content are without significant change.
Embodiment 2
(1) take 0.259gN-N-Hydroxysuccinimide, 0.431g1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride and 0.662g folic acid, be dissolved in 5mL dimethyl sulfoxide completely, place activation 4h.Taking 0.3650g chitosan adds in the glacial acetic acid solution of 15mL0.3%, and 200r/min continues stirring until and dissolves completely.Chitosan solution is slowly added in the folic acid solution of activation, simultaneously with 200r/min Keep agitation reaction 16h.With 0.1M sodium hydroxide solution, gained product is adjusted to pH9.0, and is transferred in the bag filter of 3.5KDa, dialysis 2 days in the phosphate buffered solution (PBS) of pH7.4, then dialyse 2 days in distilled water, removing impurity.Gained sample lyophilization after dialysing, obtains yellow spongy folic acid-chitosan complexes.
(2) take 0.025g curcumin, 0.700g soybean phospholipid, 0.110g cholesterol, 0.200g tween 80 be dissolved in 14mL dehydrated alcohol completely, under 45 DEG C of water bath condition, vacuum rotating removing ethanol, forms homogeneous film.Add the phosphate buffered solution (PBS) that 50mLpH6.5 concentration is 0.05M and wash film, the even suspension of formation is thick liposome.Join in DHPM by thick liposome, under 120MPa condition, Micro Fluid process 2 times, namely prepares curcumin nano-lipid body.
(3) taking 0.030g step (1) gained folic acid-chitosan complexes is dissolved in the glacial acetic acid solution of 6mL1%, and it is as clear as crystal that 200r/min continues stirring until solution, obtains folic acid-chitosan complexes solution.Getting 36mL step (2) gained curcumin nano-lipid body slowly drops in 6mL folic acid-chitosan complexes solution, and 300r/min Keep agitation reaction 2h, obtains folic acid-chitosan-modified curcumin nano-lipid body.Obtained folic acid-chitosan-modified curcumin nano-lipid body is clear yellow solution, and drug loading is 35.9mg/g phospholipid, and mean diameter is 103.1nm, zeta current potential is 16.27mv, and the coefficient of dispersion is 0.383; Folic acid-chitosan-modified curcumin nano-lipid body 24h curcumin burst size under pH7.4 environment is 18.3%, and under pH5.5 environment, 24h curcumin burst size is 26.9%; 25 DEG C store one month, and the particle diameter of folic acid-chitosan-modified curcumin nano-lipid body, surface point position and curcumin content are without significant change.
Embodiment 3
(1) take 0.653gN-N-Hydroxysuccinimide, 0.863g1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride and 1.324g folic acid, be dissolved in 10mL dimethyl sulfoxide completely, place activation 4h.Taking 0.73g chitosan adds in the glacial acetic acid solution of 30mL0.3%, and 200r/min continues stirring until and dissolves completely.Chitosan solution is slowly added in the folic acid solution of activation, simultaneously with 200r/min Keep agitation reaction 16h.With 0.1M sodium hydroxide solution, gained product is adjusted to pH9.0, and is transferred in the bag filter of 3.5KDa, dialysis 2 days in the phosphate buffered solution (PBS) of pH7.4, then dialyse 2 days in distilled water, removing impurity.Gained sample lyophilization after dialysing, obtains yellow spongy folic acid-chitosan complexes.
(2) take 0.030g curcumin, 0.840g soybean phospholipid, 0.132g cholesterol, 0.240g tween 80 be dissolved in 18mL dehydrated alcohol completely, under 45 DEG C of water bath condition, vacuum rotating removing ethanol, forms homogeneous film.Add the phosphate buffered solution (PBS) that 60mLpH6.5 concentration is 0.05M and wash film, the even suspension of formation is thick liposome.Join in DHPM by thick liposome, under 120MPa condition, Micro Fluid process 2 times, namely prepares curcumin nano-lipid body.
(3) taking 0.035g step (1) gained folic acid-chitosan complexes is dissolved in the glacial acetic acid solution of 7mL1%, and it is as clear as crystal that 200r/min continues stirring until solution, obtains folic acid-chitosan complexes solution.Getting 42mL step (2) gained curcumin nano-lipid body slowly drops in 7mL folic acid-chitosan complexes solution, and 300r/min Keep agitation reaction 2h, obtains folic acid-chitosan-modified curcumin nano-lipid body.Obtained folic acid-chitosan-modified curcumin nano-lipid body is clear yellow solution, and drug loading is 35.6mg/g phospholipid, and mean diameter is 101.7nm, zeta current potential is 16.27mv, and the coefficient of dispersion is 0.401; Folic acid-chitosan-modified curcumin nano-lipid body 24h curcumin burst size under pH7.4 environment is 17.9%, and under pH5.5 environment, 24h curcumin burst size is 27.8%; 25 DEG C store one month, and the particle diameter of folic acid-chitosan-modified curcumin nano-lipid body, surface point position and curcumin content are without significant change.
Embodiment 4
(1) take 1.036gN-N-Hydroxysuccinimide, 1.725g1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride and 2.648g folic acid, be dissolved in 10mL dimethyl sulfoxide completely, place activation 4h.Taking 1.46g chitosan adds in the glacial acetic acid solution of 15mL0.3%, and 200r/min continues stirring until and dissolves completely.Chitosan solution is slowly added in the folic acid solution of activation, simultaneously with 200r/min Keep agitation reaction 16h.With 0.1M sodium hydroxide solution, gained product is adjusted to pH9.0, and is transferred in the bag filter of 3.5KDa, dialysis 2 days in the phosphate buffered solution (PBS) of pH7.4, then dialyse 2 days in distilled water, removing impurity.Gained sample lyophilization after dialysing, obtains yellow spongy folic acid-chitosan complexes.
(2) take 0.030g curcumin, 0.840g soybean phospholipid, 0.132g cholesterol, 0.240g tween 80 be dissolved in 18mL dehydrated alcohol completely, under 45 DEG C of water bath condition, vacuum rotating removing ethanol, forms homogeneous film.Add the phosphate buffered solution (PBS) that 60mLpH6.5 concentration is 0.05M and wash film, the even suspension of formation is thick liposome.Join in DHPM by thick liposome, under 120MPa condition, Micro Fluid process 2 times, namely prepares curcumin nano-lipid body.
(3) taking 0.035g step (1) gained folic acid-chitosan complexes is dissolved in the glacial acetic acid solution of 7mL1%, and it is as clear as crystal that 200r/min continues stirring until solution, obtains folic acid-chitosan complexes solution.Getting 42mL step (2) gained curcumin nano-lipid body slowly drops in 7mL folic acid-chitosan complexes solution, and 300r/min Keep agitation reaction 2h, obtains folic acid-chitosan-modified curcumin nano-lipid body.Obtained folic acid-chitosan-modified curcumin nano-lipid body is clear yellow solution, and drug loading is 35.8mg/g phospholipid, and mean diameter is 99.3nm, zeta current potential is 16.81mv, and the coefficient of dispersion is 0.392; Folic acid-chitosan-modified curcumin nano-lipid body 24h curcumin burst size under pH7.4 environment is 16.2%, and under pH5.5 environment, 24h curcumin burst size is 28.6%; 25 DEG C store one month, and the particle diameter of folic acid-chitosan-modified curcumin nano-lipid body, surface point position and curcumin content are without significant change.
The storage stability of table 1 folic acid-chitosan-modified curcumin nano-lipid body (FA-CS-NLs-Cur)
Indicate different alphabetical person (P < 0.05) above experimental result and represent that difference has statistical significance; Indicate identical lower case person (P > 0.05) and represent no significant difference.
Claims (1)
1. a preparation method for folic acid-chitosan-modified curcumin nano-lipid body, is characterized in that:
(1) synthesis of folic acid-chitosan complexes
(1) used catalyst and each raw material and mol ratio thereof are: amino amount=6:9:9:10 in N-hydroxy-succinamide/1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride/folic acid/chitosan, N-hydroxy-succinamide, 1-(3-dimethylamino-propyl)-3-ethyl carbon ethylenediamine-hydrochloride and folic acid is taken respectively by above-mentioned mol ratio, the folic acid of 0.150g/mL concentration is dissolved in dimethyl sulfoxide, activation 4h;
(2) be that the chitosan of 0.025g/mL adds in the glacial acetic acid solution of 0.3% by concentration, it is as clear as crystal that 200r/min continues stirring until solution;
(3) folic acid solution that step (1) obtains slowly is joined in the chitosan solution that step (2) obtains, simultaneously with 200r/min Keep agitation reaction 16h;
(4) with 0.1M sodium hydroxide solution, step (3) gained product is adjusted to pH9.0, and is transferred in the bag filter of 3.5KDa, dialyse 2 days in the phosphate buffered solution and PBS of pH7.4, then dialyse 2 days in distilled water;
(5) by the lyophilization of step (4) gained solution, yellow spongy folic acid-chitosan complexes is obtained;
All operations all carries out under light protected environment;
(2) thin film dispersion-dynamic high-pressure microjet legal system is for curcumin nano-lipid body
(1) each component of liposome raw material and percentage by weight thereof are: curcumin 0.05%-0.2%, soybean phospholipid 1.4%-5.6%, cholesterol 0.22%-0.88%, tween 80 0.4%-1.6%, phosphate buffered solution and the PBS of remaining to be pH6.5 concentration be 0.05M are 91.7%-97.9%; Take curcumin, soybean phospholipid, cholesterol and tween 80 respectively by above-mentioned percentage by weight, under 45 DEG C of water bath condition, be dissolved in 15mL dehydrated alcohol by 1g soybean phospholipid, each component is dissolved completely;
(2) reduce pressure step (1) gained solution on Rotary Evaporators removing dehydrated alcohol, forms homogeneous film;
(3) add the phosphate buffered solution (PBS) that pH6.5 concentration is 0.05M and wash film, form yellow thick Liposomal suspensions;
(4) with the Liposomal suspensions that high pressure Microfluidizer treatment step (3) obtains, pressure is 120MPa, and number of processes is 2 times, obtains yellow bright curcumin nano-lipid liquid solution;
(3) preparation of folic acid-chitosan-modified curcumin nano-lipid body
(1) weight ratio of folic acid-chitosan complexes and phospholipid is 1:16.8; Be dissolved in the glacial acetic acid solution of 1% by folic acid-chitosan complexes that step () obtains by 5mg/mL, it is as clear as crystal that 200r/min continues stirring until solution;
(2) slowly join in step (two) gained curcumin nano-lipid liquid solution by above-mentioned mass ratio by step (1) gained solution, 300r/min Keep agitation reaction 2h, obtains folic acid-chitosan-modified curcumin nano-lipid body.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510671604.3A CN105287382A (en) | 2015-12-10 | 2015-12-10 | Preparation method of folic acid-chitosan modified curcumin nano-liposome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510671604.3A CN105287382A (en) | 2015-12-10 | 2015-12-10 | Preparation method of folic acid-chitosan modified curcumin nano-liposome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105287382A true CN105287382A (en) | 2016-02-03 |
Family
ID=55185681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510671604.3A Pending CN105287382A (en) | 2015-12-10 | 2015-12-10 | Preparation method of folic acid-chitosan modified curcumin nano-liposome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105287382A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109619242A (en) * | 2018-12-26 | 2019-04-16 | 孙宝泉 | For improving the nutrient solution of chrysanthemum tea color and effective component |
| CN110662532A (en) * | 2017-04-03 | 2020-01-07 | 加利福尼亚大学董事会 | Deformable Nanoscale Vehicles (DNVS) for cross-blood brain barrier, transmucosal and transdermal drug delivery |
| CN110974957A (en) * | 2019-12-06 | 2020-04-10 | 北京大学 | Application of liposome entrapping catalase and connected with PD-L1 antibody in preparation of tumor treatment drug |
| CN112056391A (en) * | 2020-09-18 | 2020-12-11 | 徐州工程学院 | Microcapsule food preservative and preparation method and application thereof |
| CN112294821A (en) * | 2019-08-02 | 2021-02-02 | 连云港金康和信药业有限公司 | Application of 5-methyltetrahydrofolic acid and composition thereof |
| CN112618558A (en) * | 2020-09-23 | 2021-04-09 | 浙江工业大学 | Erianin-adriamycin-containing double-drug co-carried liposome as well as preparation and application thereof |
| CN114432263A (en) * | 2021-12-21 | 2022-05-06 | 江苏艾兰得营养品有限公司 | Chitosan-modified lutein nanostructure lipid carrier and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010111517A1 (en) * | 2009-03-25 | 2010-09-30 | Northeastern University | Stable polyelectrolyte coated nanoparticles |
| CN101940320A (en) * | 2010-08-06 | 2011-01-12 | 南昌大学 | Preparation of medium chain fatty acid nanoliposome by using film dispersion-dynamic high-pressure microjet |
-
2015
- 2015-12-10 CN CN201510671604.3A patent/CN105287382A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010111517A1 (en) * | 2009-03-25 | 2010-09-30 | Northeastern University | Stable polyelectrolyte coated nanoparticles |
| CN101940320A (en) * | 2010-08-06 | 2011-01-12 | 南昌大学 | Preparation of medium chain fatty acid nanoliposome by using film dispersion-dynamic high-pressure microjet |
Non-Patent Citations (3)
| Title |
|---|
| GYE HWA SHIN，等: "Preparation of Chitosan-Coated Nanoliposomes for Improving the Mucoadhesive Property of Curcumin Using the Ethanol Injection Method", 《J. AGRIC. FOOD CHEM.》 * |
| 杨奎琨: "叶酸壳聚糖包覆脂质体的构建及其乳腺癌靶向研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 陈兴，等: "动态高压微射流技术制备脂质体的研究进展", 《中国农业科技导报》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110662532A (en) * | 2017-04-03 | 2020-01-07 | 加利福尼亚大学董事会 | Deformable Nanoscale Vehicles (DNVS) for cross-blood brain barrier, transmucosal and transdermal drug delivery |
| CN109619242A (en) * | 2018-12-26 | 2019-04-16 | 孙宝泉 | For improving the nutrient solution of chrysanthemum tea color and effective component |
| CN112294821A (en) * | 2019-08-02 | 2021-02-02 | 连云港金康和信药业有限公司 | Application of 5-methyltetrahydrofolic acid and composition thereof |
| WO2021023118A1 (en) * | 2019-08-02 | 2021-02-11 | 连云港金康和信药业有限公司 | Use of 5-methyltetrahydrofolic acid and composition of 5-methyltetrahydrofolic acid |
| CN110974957A (en) * | 2019-12-06 | 2020-04-10 | 北京大学 | Application of liposome entrapping catalase and connected with PD-L1 antibody in preparation of tumor treatment drug |
| CN112056391A (en) * | 2020-09-18 | 2020-12-11 | 徐州工程学院 | Microcapsule food preservative and preparation method and application thereof |
| CN112618558A (en) * | 2020-09-23 | 2021-04-09 | 浙江工业大学 | Erianin-adriamycin-containing double-drug co-carried liposome as well as preparation and application thereof |
| CN112618558B (en) * | 2020-09-23 | 2022-04-19 | 浙江工业大学 | Erianin-adriamycin-containing double-drug co-carried liposome as well as preparation and application thereof |
| CN114432263A (en) * | 2021-12-21 | 2022-05-06 | 江苏艾兰得营养品有限公司 | Chitosan-modified lutein nanostructure lipid carrier and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105287382A (en) | Preparation method of folic acid-chitosan modified curcumin nano-liposome | |
| Barani et al. | A new formulation of hydrophobin-coated niosome as a drug carrier to cancer cells | |
| Vaidya et al. | Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer | |
| Chen et al. | Nanocomplexation of soy protein isolate with curcumin: Influence of ultrasonic treatment | |
| Battaglia et al. | Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies | |
| He et al. | Green-step assembly of low density lipoprotein/sodium carboxymethyl cellulose nanogels for facile loading and pH-dependent release of doxorubicin | |
| Fan et al. | Development of calixarene-based drug nanocarriers | |
| Ye et al. | Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique | |
| Bansal et al. | Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma | |
| Wang et al. | Molecular dynamics of paclitaxel encapsulated by salicylic acid-grafted chitosan oligosaccharide aggregates | |
| Fuhrmann et al. | Modular design of redox-responsive stabilizers for nanocrystals | |
| Gu et al. | SN-38 loaded polymeric micelles to enhance cancer therapy | |
| Wang et al. | Preparation of tacrolimus loaded micelles based on poly (ɛ-caprolactone)–poly (ethylene glycol)–poly (ɛ-caprolactone) | |
| Zhang et al. | Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy | |
| Pippa et al. | Chimeric lipid/block copolymer nanovesicles: Physico-chemical and bio-compatibility evaluation | |
| WO2007086613A1 (en) | Enzymatically crosslinked protein nanoparticles | |
| WO2005060935A1 (en) | Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle | |
| Peng et al. | Amphiphilic chitosan derivatives-based liposomes: synthesis, development, and properties as a carrier for sustained release of salidroside | |
| Palma et al. | Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer | |
| Li et al. | Novel methotrexate prodrug-targeted drug delivery system based on PEG–lipid–PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C | |
| Kuznetsova et al. | Novel hybrid liposomal formulations based on imidazolium-containing amphiphiles for drug encapsulation | |
| He et al. | Core–shell structured gel-nanocarriers for sustained drug release and enhanced antitumor effect | |
| Chen et al. | Enhanced uptake and cytotoxity of folate-conjugated mitoxantrone-loaded micelles via receptor up-regulation by dexamethasone | |
| Wei et al. | The characterisation, pharmacokinetic and tissue distribution studies of TPGS modified myricetrin mixed micelles in rats | |
| Chen et al. | Toxicity, pharmacokinetics, and in vivo efficacy of biotinylated chitosan surface-modified PLGA nanoparticles for tumor therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160203 |